|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Washington Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing WashingtonLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Emergent BioSolutions Inc.
| | | Phone: | (206) 838-0500 | Fax: | (206) 838-0503 | Year Established: | 2002 | Employees: | 73 | Ticker: | EBS | Exchange: | NYSE | | Other Contacts: | Shauna M. Tholen, Senior VP & CIO Allen Shofe, Executive VP, Corporate Affairs Division Katy Strei, Senior VP, Chief Human Resources Officer Robert G. Kramer, Executive VP & CFO W. James Jackson, Ph.D., Senior VP & CSO Adam R. Havey, Executive VP & President, BioDefense Division Daniel J. Abdun-Nabi, President & CEO
| | Company Description | Emergent BioSolutions Seattle (formerly Trubion Pharmaceuticals) is a global biopharmaceutical company focused on the manufacture, development and commercialization of vaccines and antibody therapeutics. Trubion’s clinical and preclinical stage programs, as well as its novel technology platforms, will expand Emergent’s product development pipeline into the key disease indications of oncology and autoimmunity, and significantly broaden its antibody-based capabilities. The Seattle, Washington facility is now known as Emergent Product Development Seattle and will continue to focus on developing unique therapeutic products.
On August 12, 2010, Emergent BioSolutions announced an agreement to acquire Trubion Pharmaceuticals for upfront consideration of $96.8 million of value and up to $38.7 million of success-based milestones, resulting in a total consideration of up to $135.5 million. | |
|
|
|
|
|